Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.

Antimicrobial agents and chemotherapy - 1 Sept 2015

Docobo-Pérez F, Drusano G L, Johnson A, Goodwin J, Whalley S, Ramos-Martín V, Ballestero-Tellez M, Rodriguez-Martinez J M, Conejo M C, van Guilder M, Rodríguez-Baño J, Pascual A, Hope W W

Abstract excerpt

The aim of this study was to improve the understanding of the pharmacokinetic-pharmacodynamic relationships of fosfomycin against extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli strains that have different fosfomycin MICs. Our methods included the use of a hollow fiber infection model with three clinical ESBL-producing E. coli strains. Human fosfomycin pharmacokinetic profiles were simulated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Bacterial Agents
Share to Anti-Infective Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Multiple, Bacterial

Share to Escherichia coli

Share to Fosfomycin

Share to Meropenem

Share to Microbial Sensitivity Tests

Share to Thienamycins

Source

Open in PubMed Open full text

Identifiers

PMID: 26124169
DOI: 10.1128/AAC.00752-15
PMCID: PMC4538498

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacodynamics of fosfomycin: insights into clinical use for antimicrobial resistance.PMID 26124169Read ↗

Modelling biphasic killing of fluoroquinolones: guiding optimal dosing regimen design.Semantic proximity Read ↗

Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activitySemantic proximity Read ↗

Fosfomycin: evaluation of the published evidence on the emergence of antimicrobial resistance in Gram-negative pathogens.Semantic proximity Read ↗

Molecular Mechanisms and Clinical Impact of Acquired and Intrinsic Fosfomycin ResistanceSemantic proximity Read ↗

The Role of fosA in Challenges with Fosfomycin Susceptibility Testing of Multispecies Klebsiella pneumoniae Carbapenemase-Producing Clinical IsolatesSemantic proximity Read ↗

Parallel increase in community use of fosfomycin and resistance to fosfomycin in extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli.Semantic proximity Read ↗

The Combination of Fosfomycin plus Meropenem Is Synergistic for Pseudomonas aeruginosa PAO1 in a Hollow-Fiber Infection ModelSemantic proximity Read ↗

Evaluation of Fosfomycin Activity Against Extended Spectrum Beta Lactamase (ESBL) Producing Enterobacteriaceae Isolated from Three Centers of Tehran, Iran.Semantic proximity Read ↗

A mechanism-based pharmacokinetic/pharmacodynamic analysis of polymyxin B-based combination therapy against carbapenem-resistant Klebsiella pneumoniae isolates with diverse phenotypic and genotypic resistance mechanisms.Semantic proximity Read ↗

Molecular Mechanisms and Epidemiology of Fosfomycin Resistance in Staphylococcus aureus Isolated From Patients at a Teaching Hospital in ChinaSemantic proximity Read ↗

Resistance to fosfomycin: Mechanisms, Frequency and Clinical ConsequencesSemantic proximity Read ↗

The Role of <i>fosA</i> in Challenges with Fosfomycin Susceptibility Testing of Multispecies <i>Klebsiella pneumoniae</i> Carbapenemase-Producing Clinical IsolatesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.